期刊文献+

负载HER-2的树突状细胞诱导T细胞对骨肉瘤杀伤活性的研究

Anti-cancer Effect of T Lymphocyte Induced by Dendritic Cells Plused with HER-2 Antigen to Osteosarcoma
下载PDF
导出
摘要 目的:研究用HER-2抗原负载树突状细胞诱导T淋巴细胞对骨肉瘤细胞系U2-OS的杀伤活性。方法用HER-2抗原肽段E75369-377(HER-2组)、PBS(PBS组)分别负载PBMC来源的树突状细胞,与T淋巴细胞共培养7d后检测各组T细胞穿孔素的表达,通过LDH释放法比较两组T细胞对U2-OS的杀伤活性。结果 HER-2组的T细胞表达穿孔素高于PBS组(P<0.01);HER-2组的T细胞对U2-OS的杀伤率高于PBS组(P<0.01)。结论用HER-2抗原肽E75369-377负载树突状细胞诱导T细胞能提高对骨肉瘤细胞系U2-OS的杀伤效率。 Objective To investigate anti-cancer immunity of the T lymphocyte activated by dendritic cells loading of HER-2 antigen against osteosarcoma cell lines U2-OS.Methods Using HER-2 antigen peptide E75369-377(HER-2 group),PBS(PBS group)loaded PBMC-derived dendritic cells respectively,then cultured with T lymphocytes for 7 days.Detected the expression of T cells'perforin,and compared the kil ing activity of T cells in each group to U2-OS cells by LDH release assay.Results T cells in HER-2 group expressed perforin higher than PBS group(P<0.01);The kil ing rate of T cellto U2-OS cells is higher in HER-2 group than in PBS group detected by LDH release assay(P<0.01).Conclusion The U2-OS whole tumor antigen loading DC to stimulate T lymphocytes activation is bet er than synthetic peptide HER-2 antigen.With HER-2 antigen peptide E75369-377 loading dendritic cells can induce T cells to improve the ability of kil ing osteosarcoma celllines U2-OS.
作者 丁利伟 刘林 许铁 DING Li-wei;LIU Lin;XU Tie(The Graduate School of Xuzhou Medical College,Xuzhou 221004,Jiangsu,China)
出处 《医学信息(医学与计算机应用)》 2014年第21期58-59,共2页 Medical Information
关键词 树突状细胞 HER-2 骨肉瘤 免疫治疗 Dendritic cells HER-2 Osteosarcoma Immunological therapy
  • 相关文献

参考文献2

二级参考文献28

  • 1华东,黄朝晖,王丰.肿瘤患者外周血细胞毒性CD3^- CD56^+ NK细胞的扩增[J].中华微生物学和免疫学杂志,2004,24(6):455-455. 被引量:1
  • 2施明,张冰,汤紫荣,雷周云,王慧芬,冯永毅,刘敬超,范振平,李捍卫,牟劲松,王福生.肝癌患者自体细胞因子诱导杀伤细胞治疗后免疫活性细胞的检测及其临床意义[J].中华医学杂志,2003,83(23):2049-2053. 被引量:37
  • 3张锦英,束永前,黄普文,刘平,卢凯华,朱陵君,殷咏梅,穆庆霞.抗原负载树突状细胞刺激细胞因子诱导的杀伤细胞治疗晚期胃癌的临床观察[J].中国生化药物杂志,2005,26(6):336-338. 被引量:16
  • 4撒亚莲,华映坤,严新民,贾玲,孙建伟,宋建新,杨净瑜,徐艳.恶性实体瘤患者外周血细胞因子诱导的杀伤细胞增殖与杀瘤活性[J].中山大学学报(医学科学版),2006,27(1):90-92. 被引量:4
  • 5Czerniecki BJ,Koski GK,Koldovsky U,et al.Targeting HER-2/neu in early breast cacer development using dendritic cells withstaged interleukin-12 burst secretion[J].Cancer Res,2007,67(4):1842-1852.
  • 6Spector NL,Blackwell KL.Understanding the mechanisms behindtrastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer[J].J Clin Oncol,2009,27(34):5838-5847.
  • 7Yee C,Thompson JA,Byrd D,et al.Adoptive T cell therapyusing antigen-specific+T cell clones for the treatment of patientswith metastatic CD8 melanoma:In vivo persistence,migration,and antitumor effect of transferred T cells[J].Proc Natl Acad SciU S A,2002,99(25):16168-16173.
  • 8Draube A,Klein-Gonzalez N,Mattheus S,et al.Dendritic cellbased tumor vaccination in prostate and renal cell cancer:A sys-tematic review and meta-analysis[J].PLoS One,2011,6(4):1-11.
  • 9Celestia SH,Paul FS,Eric JS,et al.Integrated data from 2 ran-domized,double-blind,placebo-controlled,phase 3 trials of activecellular immunotherapy with Sipuleucel-T in advanced prostatecancer[J].Cancer,2009,115(15):3670-3679.
  • 10May KF Jr,Gulley JL,Drake CG,et al.Prostate cancer immuno-therapy[J].Clin Cancer Res,2011,17(16):5233-5238.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部